Showing 3971-3980 of 7016 results for "".
- Early vs Delayed Belimumab: 15‑Year Cost‑Effectiveness Findingshttps://reachmd.com/news/jama-netw-open-early-vs-delayed-belimumab-15year-costeffectiveness-findings/2485772/A modeled economic evaluation of biologic-naive adults with clinically active systemic lupus erythematosus compared early (≤2 years of disease duration) versus delayed initiation of intravenous belimumab
- Merz Aesthetics Marks 15 Years of XEOMIN® With New National Campaignhttps://reachmd.com/news/merz-aesthetics-marks-15-years-of-xeomin-with-new-national-campaign/2485650/Merz Aesthetics is commemorating 15 years since the US Food and Drug Administration (FDA) approved XEOMIN® (incobotulinumtoxinA) for aesthetic use, marking a milestone for the company’s flagship neurotoxin in the competitive US injectable market. Approved f
- Reduced-Dose Tralokinumab Maintains Symptom Control for Up to 1 Year in Atopic Dermatitishttps://reachmd.com/news/reduced-dose-tralokinumab-maintains-symptom-control-for-up-to-1-year-in-atopic-dermatitis/2485613/Adults with moderate-to-severe atopic dermatitis (AD) who achieved initial disease control with tralokinumab maintained improvements in symptoms and quality of life for up to 1 year following reduced dosing, according to a South Beach Symposium poster from April
- Metformin Linked to Lower 5-Year Intermediate AMD Incidence in Diabeteshttps://reachmd.com/news/metformin-linked-to-lower-5-year-intermediate-amd-incidence-in-diabetes/2485584/A population-based 5-year case-control analysis nested within a diabetic retinopathy screening program linked to general-practice prescribing records found that metformin exposure was associated with lower odds of incident intermediate AMD graded directly from images. <
- Rising Rates of Psychosis in Younger Generations: A Clinical and Service Implication Reviewhttps://reachmd.com/news/rising-rates-of-psychosis-in-younger-generations-a-clinical-and-service-implication-review/2485547/A recent study in Ontario shows a sharp rise in new psychosis diagnoses among younger birth cohorts — a finding with immediate implications for early intervention and service-capacity planning. Ne
- ORKA-001 Phase 1 Data Support Potential Once-Yearly IL-23 Dosinghttps://reachmd.com/news/orka-001-phase-1-data-support-potential-once-yearly-il-23-dosing/2485550/A half-life–extended IL-23p19 monoclonal antibody demonstrated sustained pharmacokinetics and favorable tolerability that may support once-yearly dosing in plaque psoriasis, according to “Phase 1 Clinical Data of ORKA-001, a Novel Half-Life–Extended IL-23p19 Monoclonal Antibody,” a poster by Jame
- Papillary Thyroid Cancer in Adolescents and Young Adults: Insights from Qatarhttps://reachmd.com/news/papillary-thyroid-cancer-adolescents-and-young-adults/2485375/A Qatar tertiary center study describes adolescent and young adult (AYA) papillary thyroid carcinoma (PTC) characterized by predominant classic histology and a mean tumor size of 2.19 cm. In
- skinbetter science® Marks 10 Years of AlphaRet® Technology in Retinoid-AHA Skincarehttps://reachmd.com/news/skinbetter-science-marks-10-years-of-alpharet-technology-in-retinoid-aha-skincare/2485358/skinbetter science® is marking the 10-year anniversary of its proprietary AlphaRet® technology, introduced in 2016 as one of the first topical skincare formulas to combine a retinoid with an alpha hydroxy acid (AHA). The combination, used in the flagship AlphaRet Overnight Cream, was designed to
- Yueju Pill Linked to Early Symptom Relief and Brain Biomarkers in Depressionhttps://reachmd.com/news/yueju-pill-depression-symptom-relief-biomarkers/2485204/In a randomized pilot study, the traditional Chinese medicine Yueju Pill was associated with early symptom improvement in patients with major depressive disorder, and baseline MRI‑derived str
- New Beginnings: FDA Approval of YARTEMLEA for TA-TMA Managementhttps://reachmd.com/news/new-beginnings-fda-approval-of-yartemlea-for-ta-tma-management/2485151/YARTEMLEA received FDA approval for hematopoietic stem cell transplant–associated t